Related Experiment Video
Updated: Jun 17, 2026
12:42
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
Investigational immunotherapeutics for B-cell malignancies
Alfonso Quintás-Cardama1, William Wierda, Susan O'Brien
1Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Unit 428, 1515 Holcombe Blvd, Houston, TX, 77030; aquintas@mdanderson.org.
Summary
Novel immunotherapies targeting B-cell malignancies are emerging due to rituximab resistance. These new agents, including monoclonal antibodies and T-cell engagers, offer hope but require further clinical validation and integration into treatment plans.
Area of Science:
- Hematology
- Immunology
- Oncology
Background:
- Rituximab-based chemoimmunotherapy has improved outcomes for B-cell malignancies.
- Resistance to rituximab (primary or acquired) remains a significant clinical challenge.
Purpose of the Study:
- To review promising investigational immunotherapeutics for B-cell malignancies.
- To highlight novel agents addressing rituximab resistance.
Main Methods:
- Review of current clinical and preclinical data on novel immunotherapeutics.
- Focus on agents with distinct mechanisms of action against B-cell surface antigens.
Main Results:
- Several novel agents are in late preclinical or clinical development.
- Examples include monoclonal antibodies targeting CD22, CD23, CD40, CD70, and bispecific antibodies.
- Emerging immunotherapies include small-modular immunopharmaceuticals and T-cell engagers.
Conclusions:
- Novel immunotherapeutics show promise for overcoming rituximab resistance in B-cell malignancies.
- Challenges include establishing clinical utility and integrating these agents into existing treatment protocols.
More Related Videos
Related Concept Videos
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
01:30Cancer Vaccines
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...